For any emerging or established drug developer, the New Drug Application (NDA) represents the pivotal final step in bringing a therapy to market. It is the point where years of toxicology studies, clinical trials, analytical development, and regulatory discipline converge. Because the NDA carries such immense weight—and because its success is deeply tied to the strength of the chemistry and manufacturing strategy that precedes it—sponsors increasingly look for partners with both technical capability and regulatory sophistication to help guide the journey.

At Olon USA, NDA support is not an afterthought—it is a core differentiator. And this year, their leadership in the field was amplified on a global stage when CEO Robert Poe moderated a high-profile session at AAPS PharmSci360 in San Antonio, underscoring the company’s role as a trusted authority on the scientific, business, and regulatory pathways that drive IND and NDA success.

Understanding the NDA—and Why API Strategy Shapes Its Outcome

During his AAPS panel, Poe drew an important distinction between the IND and NDA stages. The IND—the Investigational New Drug application—opens the door to first-in-human studies by presenting all preclinical toxicology work, in vivo data, and supporting information for a new molecular entity. The NDA, on the other hand, is the final commercial filing submitted after Phase 1–3 clinical trials have been completed successfully. It represents the FDA’s opportunity to evaluate whether the product can be safely and confidently approved for the market.

For API manufacturers, this shift is profound. By the time a drug reaches the NDA stage, every aspect of the synthetic process must be fully validated, fully scalable, and fully defensible in front of regulators. Analytical methods must be robust. Impurity pathways must be understood and controlled. Process scale-up must be engineered with patient safety and commercial feasibility in mind. And the sponsor must present a clean, complete, audit-ready dataset capable of withstanding FDA scrutiny.

This is the environment in which Olon USA thrives.

Thought Leadership at AAPS: Bringing Business and Science Together

Robert Poe’s role at AAPS PharmSci360 reflects Olon USA’s broader emphasis on bridging scientific excellence with sound business strategy. As the incoming Chair of the AAPS Business Development Committee for 2026, Poe helped launch a new educational series designed to help companies connect the scientific decisions made early in development to the commercial and regulatory realities they will face later.

The first session—moderated by Poe in San Antonio—focused on pre-IND and IND-enabling studies and set the stage for upcoming AAPS webinars that will address the continuum from preclinical work through NDA submission. Poe discussed how sponsors can mitigate regulatory risk, navigate the increasingly stringent expectations around analytical validation, and secure financing through the late-stage development cycle. His guidance reinforces something Olon USA sees every day: NDA success is shaped long before the application is ever filed, often by the quality of the API development strategy chosen years earlier.

Where Sponsors Commonly Struggle—and How Olon USA Helps

Many drug developers approach Olon USA after encountering early-stage challenges, especially when their API development began overseas. One of the most common issues Poe highlighted involves processes built around heavy column purification. While these methods can remove impurities, they often sacrifice 30–50% of yield—an unsustainable outcome once a molecule moves into larger-scale clinical production. Olon USA’s chemists work to redesign such processes, often eliminating purification columns altogether by adjusting the synthesis, improving starting materials, or modifying reaction pathways. The result is a cleaner, more scalable, and far more cost-effective process.

Another frequent pain point involves impurity control. Genotoxic impurities, nitrosamines, and other problematic species must be avoided, minimized, or eliminated long before NDA submission. Olon USA’s development philosophy emphasizes impurity avoidance at the design stage rather than reliance on late-stage cleanup steps. This thinking aligns closely with the FDA’s expectations for modern CMC programs.

Sponsors also often discover that the analytical methods used during Phase 1–2 are insufficient for Phase 3, where full validation becomes mandatory. Poe notes that many clients are surprised to learn that Phase 2 produced API  cannot simply be “retrofit” for Phase 3 by retesting with Phase 3methods; the rigor required at the NDA stage demands a robustness that must be built in early. Olon USA prepares clients for this heightened regulatory expectation from the beginning, ensuring that analytical methods, process controls, and documentation will hold up under FDA review.

Finally, scaling a small-molecule process from kilograms to tens or hundreds of kilograms introduces challenges that require both scientific and engineering expertise. Thermal reactions, impurity spikes, and yield drops can derail even the most promising clinical program if not properly anticipated and risk mitigation strategies implemented. Olon USA’s team is highly experienced in optimizing these transitions, ensuring safe, reproducible, and scalable manufacturing that aligns with the needs of Phase 3 and commercial production, assuring Chemistry, Manufacturing, and Controls (CMC) are in place for FDA review.

Why Sponsors Choose Olon USA for NDA-Focused API Development

The value Olon USA brings to NDA-bound programs centers on their ability to design, refine, and scale synthetic processes that are efficient, safe, impurity-controlled, and fully defensible to regulators. Their chemists evaluate multiple pathways, selecting the route that focuses on efficiency, maximizes yield, and ensures the lowest impurity burden. They understand the documentation and validation rigor required at the NDA stage and build their programs to be audit-ready from the beginning. And with three commercial-grade drugs already produced at the Concord site—and seamless integration with Olon’s global manufacturing network—they offer both the flexibility of a specialized U.S. development team and the strength of a worldwide commercial infrastructure.

Olon Worldwide is already recognized globally as a commercial manufacturing powerhouse. What many sponsors are now discovering is that Olon USA has become an equally powerful development engine, equipped to guide small-molecule APIs from preclinical batches all the way through commercial production and NDA approval.

Partnering With Olon USA for NDA Success

The NDA is more than a regulatory milestone—it is the moment a therapy transitions from possibility to reality for patients who need it. Whether a sponsor is optimizing a complex synthetic pathway, preparing for Phase 3, or assembling the documentation for FDA submission, Olon USA provides the expertise and leadership needed to bring clarity, confidence, and momentum to the process.

As emphasized during Robert Poe’s AAPS panel, aligning the business and scientific dimensions of drug development is essential—and the API strategy is often the most important place to begin that alignment.

For sponsors preparing for late-stage development or planning their journey toward NDA submission, Olon USA welcomes the opportunity to collaborate and support your program from IND to approval and beyond.